Nishimura G, Michiwa Y, Yagi H, Sato T, Fushida S, Fugimura T, Sugiyama K, Kanno M, Yonemura Y, Miwa K, Miyazaki I, Yamaguchi A
Dept. of Surgery II, Kanazawa University.
Gan To Kagaku Ryoho. 1996 Jan;23(1):69-74.
Patients who underwent curative resection for colorectal cancer between January 1987 and June 1989 were divided into two groups, to assess the usefulness of preoperative chemotherapy (400 mg UFT therapy daily for 10 days more) and to analyze changes in the proliferative activity of tumor cells. Fifty-five cases were included in the study. Thirty-three had received no preoperative chemotherapy (Group A), and 22 had received the preoperative chemotherapy (group B). The five-year cumulative survival rate was 81.1% for group A and 90.2% for Group B. The proportion of patients with no recurrence was 75.7% in Group A and 85.7% in Group B. Both parameters thus tended to be better in patients who had received preoperative chemotherapy. When PCNA labeling before UFT therapy was compared with that after UFT therapy in 13 cases, the PCNA labeling rate decreased after UFT therapy in 9 (69%) of the 13 cases. These results suggest that preoperative chemotherapy using UFT is useful in treating colorectal cancer, and that the proliferative activity of colorectal cancer can sometimes be reduced by such preoperative adjuvant therapy.
1987年1月至1989年6月间接受结直肠癌根治性切除术的患者被分为两组,以评估术前化疗(每天400毫克优福定治疗10天以上)的有效性,并分析肿瘤细胞增殖活性的变化。该研究纳入了55例患者。33例未接受术前化疗(A组),22例接受了术前化疗(B组)。A组的五年累积生存率为81.1%,B组为90.2%。A组无复发患者的比例为75.7%,B组为85.7%。因此,这两个参数在接受术前化疗的患者中往往更好。在13例患者中比较优福定治疗前和治疗后的增殖细胞核抗原(PCNA)标记情况,13例中有9例(69%)在优福定治疗后PCNA标记率下降。这些结果表明,使用优福定进行术前化疗对治疗结直肠癌是有效的,并且这种术前辅助治疗有时可以降低结直肠癌的增殖活性。